Editing AIDAVA Exploitation & Business Model (section)

== What This Means for Commercialization ==

# '''Exploitation plans exist but are strategic, not product-level.''' D6.2 and D6.8 identify directions (EHDS, citizen empowerment) but don't specify pricing, go-to-market, or product architecture.
# '''MDR certification is planned but not scoped.''' D1.3 mentions "including MDR certification" as a future product objective but no deliverable addresses the regulatory pathway.
# '''The two Go To Market approaches validate the Stamen Health thesis.'''' EHDS compliance infrastructure (approach 1) and patient data apps (approach 2) are the same opportunities Stamen is pursuing.
# '''The gap is reliability:''' 45% automation with suboptimal tools. Commercial viability needs 80%+. This is an engineering problem, not a research problem — the architecture is right, the execution needs hardening.
# '''Patient-perceived value is weak.''' G1 showed "lack of direct benefits" as a concern. The product needs to demonstrate immediate, tangible value to patients — not just future research benefits.

See also: [[AIDAVA]], [[AIDAVA Documents]], [[Stamen Health]], [[PHKG Business Opportunities]], [[Stamen Health Executive Summary]]

[[Category:Project]][[Category:EU]]